You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Details for New Drug Application (NDA): 209471


✉ Email this page to a colleague

« Back to Dashboard


NDA 209471 describes COMBOGESIC, which is a drug marketed by Aft Pharms Us and Hikma and is included in two NDAs. It is available from two suppliers. There are eight patents protecting this drug. Additional details are available on the COMBOGESIC profile page.

The generic ingredient in COMBOGESIC is acetaminophen; ibuprofen sodium. There are sixty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetaminophen; ibuprofen sodium profile page.
Summary for 209471
Tradename:COMBOGESIC
Applicant:Aft Pharms Us
Ingredient:acetaminophen; ibuprofen
Patents:3
Pharmacology for NDA: 209471
Mechanism of ActionCyclooxygenase Inhibitors
Suppliers and Packaging for NDA: 209471
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
COMBOGESIC acetaminophen; ibuprofen TABLET;ORAL 209471 NDA Hikma Pharmaceuticals USA Inc 0143-9432 0143-9432-27 250 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0143-9432-27)
COMBOGESIC acetaminophen; ibuprofen TABLET;ORAL 209471 NDA AFT Pharmaceuticals US, Inc. 72260-129 72260-129-01 250 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72260-129-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength325MG;97.5MG
Approval Date:Mar 1, 2023TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 1, 2026
Regulatory Exclusivity Use:NEW PRODUCT
Patent:⤷  Sign UpPatent Expiration:Sep 22, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:A METHOD OF TREATING MILD TO MODERATE ACUTE PAIN IN ADULTS BY ADMINISTERING 975-1000 MG OF ACETAMINOPHEN AND 292.5-300 MG OF IBUPROFEN IN A SINGLE ADMINISTRATION
Patent:⤷  Sign UpPatent Expiration:Feb 27, 2039Product Flag?YSubstance Flag?Delist Request?
Patented Use:A METHOD OF TREATING MILD TO MODERATE ACUTE PAIN IN ADULTS BY ADMINISTERING 975-1000 MG OF ACETAMINOPHEN AND 292.5-300 MG OF IBUPROFEN IN A SINGLE ADMINISTRATION

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.